A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia

The change in plasma arginine vasopressin concentration (P[AVP]) in response to osmotic stimulation (POsm) can be used as a biomarker for NMDA receptor signalling in schizophrenia and depression, distinguishing between these mental illnesses?
In response to hyperosmotic challenge, depressed subjects showed increased P[AVP] response in comparison with healthy control and schizophrenic subjects. 

 Read the research paper:
http://onlinelibrary.wiley.com/doi/10.1113/EP086212/full

Comments

Post a Comment

Popular posts from this blog

First New Drug for Liver Cancer in a Decade: Regorafenib

The US Food and Drug Administration (FDA) has expanded the indication for regorafenib ( Stivarga , Bayer) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug sorafenib ( Nexavar , Bayer). Expansion of regorafenib's indication marks the first FDA-approved treatment for a liver cancer in almost a decade! Medscape article: http://www.medscape.com/viewarticle/879216?src=soc_fb_170427_mscpedt_news_onc_livercancer
Read more